Pictilisib (strong PI3Kα/δ, modest PI3Kβ/γ inhibitor) treatment had little effect on the proliferation of ER− breast cancer cells, whereas combined pictilisib and LGK-974 (PORCN inhibitor) treatment synergistically reduced ER− breast cancer cell proliferation [107]. Here, PORCN is linked to breast cancer.